Accéder au contenu
Merck

Congenital muscular dystrophy and generalized epilepsy caused by GMPPB mutations.

Brain research (2014-05-02)
Alya R Raphael, Julien Couthouis, Sarada Sakamuri, Carly Siskind, Hannes Vogel, John W Day, Aaron D Gitler
RÉSUMÉ

The alpha-dystroglycanopathies are genetically heterogeneous muscular dystrophies that result from hypoglycosylation of alpha-dystroglycan (α-DG). Alpha-dystroglycan is an essential link between the extracellular matrix and the muscle fiber sarcolemma, and proper glycosylation is critical for its ability to bind to ligands in the extracellular matrix. We sought to identify the genetic basis of alpha-dystroglycanopathy in a family wherein the affected individuals presented with congenital muscular dystrophy, brain abnormalities and generalized epilepsy. We performed whole exome sequencing and identified compound heterozygous GMPPB mutations in the affected children. GMPPB is an enzyme in the glycosylation pathway, and GMPPB mutations were recently linked to eight cases of alpha-dystroglycanopathy with a range of symptoms. We identified a novel mutation in GMPPB (p.I219T) as well as a previously published mutation (p.R287Q). Thus, our work further confirms a role for GMPPB defects in alpha-dystroglycanopathy, and suggests that glycosylation may play a role in the neuronal membrane channels or networks involved in the physiology of generalized epilepsy syndromes. This article is part of a Special Issue entitled RNA Metabolism 2013.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-α-dystroglycane, clone VIA4-1, culture supernatant, clone VIA4-1, Upstate®
Sigma-Aldrich
Anticorps anti-laminine α2, clone 5H2, ascites fluid, clone 5H2, Chemicon®